Jump Financial LLC Makes New $453,000 Investment in Alkermes plc (NASDAQ:ALKS)

Jump Financial LLC purchased a new stake in Alkermes plc (NASDAQ:ALKS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,739 shares of the company’s stock, valued at approximately $453,000.

Other large investors also recently made changes to their positions in the company. Natixis Advisors LLC grew its position in shares of Alkermes by 36.8% during the 4th quarter. Natixis Advisors LLC now owns 49,922 shares of the company’s stock worth $1,436,000 after buying an additional 13,432 shares during the period. JPMorgan Chase & Co. grew its holdings in Alkermes by 147.4% during the fourth quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company’s stock valued at $25,581,000 after purchasing an additional 529,962 shares during the period. Barclays PLC increased its stake in Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after purchasing an additional 220,893 shares in the last quarter. Savant Capital LLC raised its holdings in Alkermes by 11.6% in the fourth quarter. Savant Capital LLC now owns 11,075 shares of the company’s stock worth $319,000 after purchasing an additional 1,152 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Alkermes by 558.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock valued at $85,000 after buying an additional 2,502 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Insider Activity

In other Alkermes news, EVP Craig C. Hopkinson sold 100,918 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the transaction, the executive vice president now owns 44,290 shares of the company’s stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.89% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ALKS shares. Royal Bank of Canada initiated coverage on Alkermes in a report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 target price on the stock. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $21.00 to $38.00 in a research report on Tuesday, March 4th. HC Wainwright restated a “neutral” rating and set a $46.00 target price on shares of Alkermes in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group increased their price objective on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Alkermes Stock Performance

ALKS opened at $27.67 on Friday. The business’s 50-day simple moving average is $32.08 and its 200 day simple moving average is $30.38. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45. The firm has a market capitalization of $4.56 billion, a PE ratio of 12.75, a PEG ratio of 2.20 and a beta of 0.39.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, research analysts forecast that Alkermes plc will post 1.31 earnings per share for the current year.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.